4.0 Article

Macular vitelliform lesion in desferrioxamine-related retinopathy

Journal

DOCUMENTA OPHTHALMOLOGICA
Volume 121, Issue 2, Pages 161-166

Publisher

SPRINGER
DOI: 10.1007/s10633-010-9236-z

Keywords

Desferrioxamine toxicity; Macular vitelliform lesion; Electroretinogram measurement

Categories

Funding

  1. Foundation Fighting Blindness, Owings Mills, Maryland
  2. Grant Healthcare Foundation, Lake Forest, Illinois
  3. NIH [EYO1792]
  4. Research to Prevent Blindness

Ask authors/readers for more resources

To report a case of a macular vitelliform lesion associated with desferrioxamine treatment. Ocular, electrophysiological, psychophysical, perimetric, fluorescein angiographic, fundus autofluorescence, and spectral-domain OCT examinations were obtained on a 45-year-old Caucasian woman with thalassemia major treated with blood transfusions and desferrioxamine. The patient was observed to have a vitelliform macular lesion in the right eye with a hypopigmented macular lesion and retinal pigment mottling in the left. At the most recent follow-up visit, best-corrected visual acuity was 20/70 in the right eye and 20/25 in left. Full-field electroretinogram (ERG) testing showed normal cone and rod responses. Mild localized elevations of rod psychophysical thresholds were found. A vitelliform macular lesion can develop in patients treated with desferrioxamine. Some such patients may not show diffuse photoreceptor cell functional loss as determined by electrophysiological testing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available